New prospective cohort study and Mendelian randomization analysis reveal a link between psoriasis and cardiovascular risk via elevated plasma triglycerides.

Competing Interests: Conflicts of interest J.M.G. has served as a consultant for AbbVie, Artax [data and safety monitoring board (DSMB)], BMS, Boehringer Ingelheim, Celldex (DSMB), FIDE (which is sponsored by multiple pharmaceutical companies), GSK, Inmagene (DSMB), Twill, Lilly [data monitoring committee (DMC)], LEO, MoonLake (DSMB), Janssen Biologics, Novartis, UCB (DSMB), Neuroderm (DSMB) and Veolia North America, receiving honoraria; receives research grants (to the Trustees of the University of Pennsylvania) from Amgen, BMS and Pfizer; and received payment for continuing medical education work related to psoriasis that was supported indirectly by pharmaceutical sponsors. J.M.G. is a co-patent holder of resiquimod for the treatment of cutaneous T-cell lymphoma. J.M.G. is a Deputy Editor of the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology, is Chief Medical Editor for Healio Dermatology (receiving honoraria) and is a member of the Board of Directors for the International Psoriasis Council and the Medical Dermatology Society, receiving no honoraria.